Reverb Therapeutics
Latest round
- Seed
Last raised
- Feb 2025
Total raised
- $12M
Investors
- 6
About Reverb Therapeutics
Reverb Therapeutics Inc. is a biotechnology company focused on the innovative development of bispecific antibodies that leverage the natural immune system to enhance therapeutic outcomes for various diseases. Reverb Therapeutics Inc. was founded in 2023 in Vancouver, Canada, and specializes in creating bispecific antibodies for therapeutic applications. In February 2025, Reverb Therapeutics Inc. Reverb Therapeutics specializes in the development of bispecific antibodies that harness the therapeutic potential of the natural immune system. Their core product offerings revolve around the Amplify·R platform, which is designed to amplify natural cytokine signaling, aiming to enhance immune responses for diverse therapeutic applications. The primary use cases these products aim to address include various malignancies and autoimmune diseases, with a focus on improving patient outcomes through innovative treatment modalities. The company serves a range of stakeholders in the biopharmaceutical sector, with potential end users including healthcare providers and patients suffering from conditions that require enhanced immune interventions.Reverb Therapeutics' revenue generation model is primarily based on partnerships and collaborations with other biopharmaceutical entities, leveraging their research and development capabilities. Transactions typically occur through strategic alliances that may include co-development agreements, licensing deals, and research collaborations, allowing them to monetize their proprietary technologies. The company’s offerings, particularly the bispecific antibodies developed through the Amplify·R platform, are poised to attract interest from pharmaceutical companies seeking to enhance their product pipelines. Specific pricing plans and financial structures related to their products and services are not disclosed, but the nature of these partnerships suggests a focus on milestone payments and potential royalties based on the commercialization success of their therapeutic innovations. The company is focused on launching new products designed to enhance immune responses, thereby addressing critical healthcare needs. Reverb is also exploring expansions into additional markets across North America and Europe by the end of 2025, aiming to strengthen their presence in regions with robust biopharmaceutical research activities.
Who invested in Reverb Therapeutics
6 investors across 1 round
See all investors in Reverb Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Feb 19, 2025
Amount
$12M
Investors
Questions about Reverb Therapeutics
Who invested in Reverb Therapeutics?
Reverb Therapeutics has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Reverb Therapeutics raised?
Reverb Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Reverb Therapeutics last raise money?
Reverb Therapeutics's most recent round on record is a Seed, in Feb 2025.
What does Reverb Therapeutics do?
Reverb Therapeutics is a biotechnology company.
Where is Reverb Therapeutics headquartered?
Reverb Therapeutics is headquartered in Vancouver, Canada.
Which VCs invest in companies like Reverb Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Reverb Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Reverb Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.